We are excited to share that Biocytogen will attend Oligonucleotides for CNS Summit Europe, from April 21st - 23rd in the Netherlands. Europe’s oligonucleotides sector is entering a defining moment, with major collaborations between pharmaceutical companies and advancements in RNA-targeted approaches for CNS diseases. This is a fantastic opportunity to exchange new ideas and network with industry leaders!
What is Oligonucleotides for CNS Summit Europe?
Oligonucleotides for Central Nervous System (CNS) Summit Europe is the first ever European forum centered solely on CNS oligonucleotide therapeutics. There will be 60+ attendees from neurobiology, oligonucleotide chemistry, PK/PD, in vivo translation and CNS delivery, joining together for three days of thought-provoking discussions on latest technologies that are enhancing the understanding of diseases and biomarkers for oligo targeting.
Event Overview
Date: April 21st - 23rd, 2026
Venue: Novotel Amsterdam Schiphol Airport, Taurusavenue 12, 2132 LS Hoofddorp, Netherlands
Event Schedule
For more information, please refer to the agenda here.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to connecting with you in Amsterdam, Netherlands!
